Poster

A novel concomitant NRAS and BRAF mutation in metastatic colorectal cancer

BackgroundTarget therapy in metastatic colorectal cancer needs the determination of KRAS, NRAS, and BRAF mutation status to identify patients resistant to anti-EGFR treatment. RASgenes (K...

06/25/2023

Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis

BackgroundRegorafenib has been shown to improve survival in later lines of treatment of metastatic colorectal cancer patients, irrespective of RAS status. This study aimed to retrospectiv...

06/25/2023

Safety and efficacy of short cetuximab infusion for patients with metastatic colorectal cancer

BackgroundCetuximab is an FDA approved anti-EGFR monoclonal antibody that is given to patients with metastatic colorectal cancer (mCRC) who are KRAS and NRAS wildtype (wt). Dosing of cetu...

K. Alshammari ;

F. Alotaibi ;

H. Shehata ;

M. Alkaiyat ;

J. Al Qahtani ;

A. Alolayan ;

M. Algarni ;

Mohamed M. Ali ;

A. Abushara ;

A. Al-Abdulaali ;

06/25/2023

Tumor regression and nodal status to neoadjuvant chemotherapy as a prognostic marker in patients with locally advanced gastric and gastroesophageal cancer

BackgroundGastric cancer is one of the most common malignancies with a poor prognosis. In the western population, it is diagnosed mainly as a locally advanced disease. Surgical treatment ...

06/25/2023

Comparison of KRAS status between primary colorectal tumor and metastasis or recurrent tumor

BackgroundPrevious NGS experiments showed that distinct parts of the same tumor showed different mutation profiles. Additionally, primary tumors and their metastases can differ in their m...

06/25/2023

Prospective, observational study evaluating the effectiveness and safety of aflibercept plus FOLFIRI in metastatic colorectal cancer (mCRC) according to Polish reimbursement criteria

BackgroundAflibercept plus FOLFIRI was approved in Poland in 2017 for the treatment of mCRC patients aprior oxaliplatin-based regimen, based on results of VELOUR phase III trial (Van Cuts...

06/25/2023

Outcomes of phosphorus-32 microparticle intratumoural implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma

BackgroundMetastatic pancreatic adenocarcinoma (mPDAC) has a poor prognosis with a 5-year survival rate of 3%. In non-metastatic, unresectable locally advanced pancreatic cancer (LAPC) pa...

06/25/2023

The impact of genomic alterations on response rate and survival outcomes in advanced BTC patients who receive cisplatin/gemcitabine plus durvalumab in clinical practice

BackgroundThe TOPAZ-1 phase III trial reported a survival benefit with the anti-programmed death cell ligand 1 (anti-PD-L1) durvalumab in combination with cisplatin/gemcitabine in patient...

06/25/2023

A single arm phase II trial of capecitabine and erlotinib in patients with advanced hepatocellular carcinoma after first-line failure (CAPER- HCC study)

BackgroundLow dose capecitabine in combination with erlotinib has potential anti-tumor activity with limited toxicity, a cost-effective option for advanced hepatocellular carcinoma (HCC)....

06/25/2023

Proteomic identifies heterogeneity of AFP-negative hepatocellular carcinoma

BackgroundHepatocellular carcinoma (HCC) is the third leading cause of cancer-associated mortality worldwide. Alpha-fetoprotein (AFP) is the most commonly used diagnostic marker for HCC. ...

06/25/2023